MeMed has also developed the MeMed COVID-19 Severity™ test for predicting severe outcomes in COVID-19 patients, which has been cleared for use in Europe. Eran Eden, MeMed’s co-founder and CEO, said: “This new investment will enable MeMed to expand operations with a focus on the U.S.